RADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
Actor portrayals.
This user guide provides step-by-step navigation of the HCP Portal, where you can enroll RADICAVA ORS® patients in the JourneyMate Support Program™and access updates and information for patients who provided authorization.
Download the Benefit Investigation and Enrollment Form (BIF) to prescribe RADICAVA ORS® and enroll patients in the JourneyMate Support Program™.
Use this checklist to facilitate a common understanding of the steps involved in coordinating treatment initiation for RADICAVA ORS®.
RADICAVA ORS® is only available through an in-network pharmacy. This flashcard provides information about how the specialty pharmacy provides RADICAVA ORS® to patients and includes contact information for the specialty pharmacies.
This letter may be considered if your patient’s request for an exception is denied.
This letter may be considered if your patient’s coverage is denied because the prescribed medication is not on your patient’s health plan formulary, or for another reason.
Outlines documentation that may be required for the Prior Authorization process and the importance of providing this information to your patient’s health plan.
Use with your patients to help them navigate options that may be available to them to help cover applicable out-of-pocket costs associated with their prescribed RADICAVA ORS® medication.
Learn more about the Out-of-Pocket Assistance Program for RADICAVA ORS® for your patients.
Review the history of clinical and real-world experience that supports RADICAVA ORS® treatment—the ONLY FDA-approved oral form of edaravone.
Review the Prescribing Information for RADICAVA ORS®.
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings
Patients can use this information to better understand the steps to receiving their medication from a specialty pharmacy. It includes contact information for the in-network specialty pharmacies that may fulfill their prescription for RADICAVA ORS® (edaravone).
Helpful information on what you can expect when you receive your RADICAVA ORS® shipments, including contents of the Starter Kit and Maintenance Kit, and details about taking RADICAVA ORS®.
Patients can use this brochure to learn about the different formulations of edaravone and the steps to starting or switching treatments.
Help patients understand their health insurance coverage and potential out-of-pocket costs for treatment with RADICAVA ORS®.
Help patients understand their coverage options. This brochure does not include a complete list of health plan options.
Provide patients with information about government health plan options that may be available.
Patient authorization is required to complete a BIF. Patients can provide this authorization online or via mail, fax, or electronic fax.
This resource helps patients understand that RADICAVA ORS® is on the VA National Formulary. It also provides information about treatment eligibility, benefit access, and other resources for veterans.2
This brochure is designed to help qualified Medicare Part D patients understand how they may be able to save on their prescription drugs with the LIS Program. This brochure does not include a complete explanation of the program.
Learn about the Patient Assistance Program for uninsured patients who are in financial need.
Provide information about the Out-of-Pocket Assistance Program for RADICAVA ORS® for eligible patients with commercial insurance.
Patients can complete and submit this form to the JourneyMate Support Program™ Insurance & Access Specialist to enroll in the Out-of-Pocket Assistance Program.
Share this brochure with patient to educate them on the history of clinical and real-world experience that supports RADICAVA ORS® treatment - the ONLY FDA-approved oral form of edaravone.
This resource will improve your patients' and caregivers' understanding about RADICAVA ORS® as well as the treatment and care that is extended by you and your team.
Helpful information for care partners about this oral treatment.
Provide patients with more information about receiving RADICAVA ORS®.
This guide helps patients understand when and how to take RADICAVA ORS®.
Review these step-by-step instructions on taking RADICAVA ORS®.
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings 2. US Department of Veterans Affairs. Pharmacy benefits management services. Search: edaravone. Accessed July 25, 2022. https://www.pbm.va.gov/apps/VANationalFormulary/
Revise la información de prescripción para RADICAVA ORS® (edaravone).
Proporcione a los pacientes más información sobre cómo recibir RADICAVA ORS® (edaravone).
Revise las instrucciones para tomar RADICAVA ORS®.
Revise la información útil sobre este tratamiento oral.
Obtenga orientación paso a paso para tomar RADICAVA ORS®.
El folleto del Programa de Asistencia de Bolsillo para RADICAVA ORS® proporciona información sobre el Programa de Asistencia de Bolsillo para pacientes elegibles con seguro comercial.
Se requiere la autorización del paciente para completar un BIF. Si aún no ha firmado un BIF y desea inscribirse en el Programa de apoyo JourneyMate Support Program™, puede firmar este formulario para inscribirse en los servicios del Programa de apoyo JourneyMate Support Program™. Puede proporcionar esta autorización en línea o por correo postal, o por fax.
Los pacientes pueden acceder a estos útiles videos en español en el sitio web para pacientes que reciben RADICAVA ORS®
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings 2. US Department of Veterans Affairs. Pharmacy benefits management services. Search: edaravone. Accessed July 25, 2022. https://www.pbm.va.gov/apps/VANationalFormulary/
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
RADICAVA, RADICAVA ORS, the RADICAVA ORS logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation.
JourneyMate Support Program is a trademark of Mitsubishi Tanabe Pharma America, Inc.
All other company names, product names, trade/service marks or other trade names are the property of their respective owners.
For US Healthcare Professionals Only.
© 2024 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-OE-US-0981 04/25
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.
